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Incidence of Venous Thromboembolism in
cancer patients treated with Cisplatin
based chemotherapy — a cohort study
Muhammad Nauman Zahir1*, Quratulain Shaikh2, Munira Shabbir-Moosajee1 and Adnan Abdul Jabbar1
Abstract
Background: Cancer related thrombosis not only increases morbidity and mortality but also poses a significant
financial burden on health care system. Risk of venous thromboembolism (VTE) in these patients substantially
increases with the addition of chemotherapy. Lately, cisplatin has been implicated as an independent factor. There
is little data estimating the risk of venous thromboembolism in patients receiving cisplatin based chemotherapy
when compared to other chemotherapeutic agents.
Methods: Patients who had received chemotherapy between November 2010 and October 2012 were
retrospectively identified from a single institute cancer registry. 200 patients who had received cisplatin based
chemotherapy were identified as the exposed group while 200 patients who had received non-Cisplatin based
regimens were identified as the non-exposed group. Patients were followed for development of VTE throughout
the entire duration of therapy and one month thereafter. Cox proportional hazard model was used to compute
relative risks with 95% confidence intervals.
Results: The baseline characteristics were similar in the two groups. Mean age for the entire cohort was 55.4 ± 10.
7 years and male to female ratio was almost 1:1. On univariate analysis, cisplatin based chemotherapy, presence of
central venous catheter, female gender, poor performance status, high risk stratification according to the Khorana
model and use of granulocyte colony stimulating factor were all significantly associated with the development of
VTE. The crude relative risk for the incidence of VTE in cisplatin group was 2.8 (95% CI, 1.4 – 4.2) times compared to
the non-Cisplatin group. When the relative risk was adjusted for the above variables in multivariable analysis, it
increased to 3.3 (95% CI, 1.6 – 6.8) compared to the control group.
Conclusion: A high incidence of VTE in patients receiving cisplatin based chemotherapy was demonstrated in this
study. Prospective studies are warranted to establish this observation with certainty and to explore the possible use
of thromboprophylaxis in patients receiving cisplatin based chemotherapeutic regimens.
Keywords: Cisplatin, Chemotherapy, Venous thromboembolism
Background
There is a substantial risk of venous thromboembolic
events (VTE) in patients with cancer. The incidence
of VTE in the general population is approximately
117 per 100,000, whereas the incidence in patients
with cancer is approximately one in 200 [1, 2]. A
large cohort study showed that the baseline risk of
thrombosis in cancer is approximately 4.1 folds com-
pared to the healthy population while it increases to
6.5 fold after the addition of chemotherapy [3]. This
leads to reduction in survival of patients with malig-
nancy and increased expense of treatment and care
[4–6]. Although individual factors including the
tumor type, stage, recency of cancer diagnosis, pres-
ence and number of co-morbidities define risk of
VTE in cancer, active therapy with certain chemother-
apeutic agents has been contemplated as an additional
risk factor [7]. There is anecdotal evidence of
* Correspondence: nauman.zahir@gmail.com
1Department of Oncology, Aga Khan University Hospital, Stadium Road, PO
BOX: 3500, Karachi 74800, Pakistan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zahir et al. BMC Cancer  (2017) 17:57 
DOI 10.1186/s12885-016-3032-4
increased incidence of VTE in patients receiving
Cisplatin based regimes [8, 9]. Studies in urothelial,
germ cell and non-small cell lung cancer (NSCLC)
patients have established a link between Cisplatin and
increased incidence of VTE [10–12]. Another recent
large retrospective study showed the prevalence of
VTE to be 16.6% in all patients treated with Cisplatin
[13] which is significantly higher than 7.3% for VTE
in patients treated with any chemotherapy [14]. Pro-
spective randomized controlled trials in patients with
advanced esophagogastric junction (EGJ) or gastric
adenocarcinoma showed that this thrombogenic effect
is not class specific for all the platinum containing
chemotherapeutic agents, but only Cisplatin based
chemotherapy is associated with a statistically signifi-
cant greater number of VTE events than Oxaliplatin
[15, 16]. Recently, a meta-analysis from case series
and some pre-clinical trials provided evidence of high
risk of VTE in patients receiving Cisplatin based regi-
mens [17].
Various hypotheses exist pertaining to the mechanisms
associated with Cisplatin associated thrombosis includ-
ing direct damage to the vascular endothelium, in-
creased procoagulant activity, reduced anticoagulation
synthesis, platelet activation and aggregation and vascu-
lar inflammation [18–24].
Despite increasing evidence pertaining to the
thrombogenic potential of Cisplatin, no original analyt-
ical study has thus far investigated the magnitude of in-
creased risk of VTE imparted by Cisplatin based
chemotherapies when compared to other chemother-
apies. Hence, it is extremely important to quantify this
risk in order to advocate prophylaxis with antiplatelets
or anticoagulants and hence reduce the economic and
health care associated burden of VTE caused by
Cisplatin based chemotherapy. Therefore we aimed to
quantify the risk and identify high risk groups so that
treatment is targeted and benefits maximized. Prophy-
lactic anticoagulation for all cancer patients is expensive
and has a narrow therapeutic index and hence not prac-
tical. We hypothesized that there is an increased risk of
VTE in cancer patients receiving Cisplatin based chemo-
therapy regimens compared to other chemotherapies.
Methods
This is a retrospective cohort study including all adult
cancer patients presenting to the oncology ward or
day care centre of the Aga Khan University Hospital
for chemotherapy. Cancer patients receiving Cisplatin
based chemotherapy regimens were considered ex-
posed while those cancer patients receiving chemo-
therapy regimens which do not contain Cisplatin
comprised the unexposed group. Adult (>16 years)
participants were considered eligible if they received
treatment between November 1, 2010 and October
31, 2012. They should have initiated and completed
all treatment at Aga Khan University Hospital while
maintaining a followup of atleast 1 month post com-
pletion of treatment or until death, whichever came
first. Excluded were those on antiplatelets agents or
anticoagulants, with a previous history of DVT or PE
(self-reported), known pro-thrombotic disorders or
hyper-coagulable states, patients who were on
erythropoiesis-stimulating agent (ESA) during chemo-
therapy or up to 6 weeks prior to the first cycle of
chemotherapy and those female patients who were on
oral contraceptive pills.
All cancer patients treated in the day care centre or
the inpatient oncology wards of Aga Khan University
Hospital between November 1, 2010 and October 31,
2012 were identified through the discharge coding
system. 100 consecutive eligible patients were in-
cluded in each group starting from November 1, 2010
(Fig. 1). Medical record files were reviewed for demo-
graphic and clinical data which was recorded on a
pre-designed questionnaire. Confounding factors such
as the presence of indwelling central line, obesity and
family history of DVT were recorded if present. All
identified patients were followed up during the course
of chemotherapy and at least 4 weeks post chemo-
therapy. Radiological investigations for the study
population were also reviewed to make sure that no
cases of VTE are missed. In case of discrepancy be-
tween the chart data and radiological investigations,
the patient was telephonically evaluated for the his-
tory of VTE event or the use of anticoagulant agents
during the specified time period. Outcome was any
VTE event during chemotherapy or within 4 weeks
after the completion of chemotherapy. ECOG classifi-
cation was modified for analysis as class 0, 1 and 2
were combined as “good”, while class 3 and 4 was
“poor”. Class 5 was excluded. Khorana score was cat-
egorized as low risk (0 points), intermediate risk (1–2
points) and high risk (3 or more points).
Outcome
Venous thromboembolism
Venous Thromboembolism was defined as the occur-
rence of a thromboembolic event after atleast 3 days of
initiation of chemotherapy up to 4 weeks of the comple-
tion of chemotherapy cycle. This included any deep ven-
ous thrombosis and/or pulmonary embolism as under:
1. Evidence of venous thromboembolism on Computed
Tomography Chest.
2. Evidence of DVT anywhere in the body on
radiological evaluation including ultrasound, CT
scan or MRI within the period defined above
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3. Cause of death/morbidity defined as Pulmonary
Embolism by primary physician.
4. For patients who develop signs and symptoms of
VTE but died before diagnostic criteria could be
met, sudden, otherwise unexplained death was taken
as a VTE event in the presence of severe hypoxia on
ABGs and no acute change in chest
X-ray.
With a confidence level of 95%, power of 80% and
considering the prevalence of venous thromboembol-
ism in cancer patients receiving chemotherapy to be
around 7.3% while the anticipated prevalence after re-
ceiving Cisplatin chemotherapy to be 16.6% the mini-
mum sample size in each group to refute the
hypothesis of equality of proportions was 200 [14].
Patients were enrolled after informed consent. Ethical
approval was taken from the Institutions’ Ethics
Committee under approval number 2703-Med-ERC-
2013. Complete confidentiality of all patient informa-
tion and personal data was ensured.
Statistical analysis
Mean ± SD was reported for continuous variables and
percentages and proportions for categorical variables. Cox
proportional hazard model was used to calculate crude
and adjusted Relative risks and 95% confidence interval
for incidence of VTE. p value < 0.05 was considered
significant. Data was analysed using Stata version 12.
Results
The mean age of Cisplatin group was 56(11.9) years while
in the non-Cisplatin groups it was 55(9) years. There was
a slight preponderance of males in both groups (Table 1).
Most of the cancers were metastatic in both groups and
very few were early stage malignancies (Tables 2 and 3).
Less than 10% of the whole cohort had ECOG poor status.
129(64.5%) participants in Cisplatin group had intermedi-
ate Khorana risk score as compared to 125(62.5%) in the
Non-Cisplatin group. 29% of the patients had an indwell-
ing central venous catheter (CVC) at some point during
the study in the Cisplatin group vs. 27% in the non-Cispla-
tin group. Details of the chemotherapy regimens used in
both groups have been highlighted in Tables 4 and 5
whereas important co-morbids in the two cohorts have
been summarized in Table 6.
When the dose of Cisplatin was considered, we found
that 31 VTE events occurred when the mean (SD) cu-
mulative dose of Cisplatin was 471(133) mg/m2 while in
the group without events the mean cumulative dose was
322(124) mg/m2 (Table 7).
Among the VTE events most were DVTs i.e.18 in
Cisplatin group while 7 in non-Cisplatin group
(Appendix 1). Among those who suffered a VTE event, 4
Fig. 1 Flow chart of participants in the study. *Aga Khan University Hospital, Karachi, Pakistan
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died in Cisplatin group while 1 in non-Cisplatin group
(Appendix 2). On univariate analysis other than
Cisplatin based chemotherapy, poor ECOG status,
presence of CVC and Khorana risk score were
statistically significant (Appendix 3). These were used
for final model building.
The crude relative risk of VTE in the Cisplatin
group was 2.8 (95% CI: 1.4–4.22) times higher than
in the Non-Cisplatin group (Table 8). When adjusted
by gender, ECOG status, GCSF, presence of CVC and
Khorana risk score the adjusted relative risk was
3.32(95% CI:1.6–6.8) (Table 9).
Discussion
This study reports a high risk (RR: 3.3, 95% CI: 1.6–
6.8) of VTE in cancer patients receiving Cisplatin
based chemotherapy. Cisplatin is a platinum based
drug which is used for the treatment of cancer. The
mechanism of causing VTE is not clear but endothe-
lial injury, hypomagnesemia and increased levels of
Von Willebrand’s factor are involved [8, 19–21, 23].
Patient factors including female sex, age, type of
cancer, Khorana risk and indwelling CVC further
elevate the risk of VTE [13]. In our study Khorana
risk and presence of CVC were found to be
significantly associated with this risk. Another interesting
finding, which has not been explored previously, is the risk
of VTE with higher cumulative doses of Cisplatin (Table 3).
In our study, cumulative Cisplatin dose of more than
450 mg was associated with VTE events.
Table 2 Cancer type and stage of patients receiving cisplatin
based chemotherapy
Site of cancer Stage of tumor (N = 200) Total (%)
Early
(%)
Locally
advanced (%)
Metastatic
(%)
Lung 1 (0.5) 16 (8) 21 (10.5) 38 (19)
Gastric/GEJ 2 (1) 8 (4) 10 (5) 20 (10)
Head and Neck 1 (0.5) 14 (7) 19 (9.5) 34 (17)
Pancreatic 0 4 (2) 9 (4.5) 13 (6.5)
Ovarian 1 (0.5) 5 (2.5) 0 6 (3)
Esophageal 1 (0.5) 6 (3) 9 (4.5) 16 (8)
Germ Cell 3 (1.5) 1 (0.5) 9 (4.5) 13 (6.5)
Cervical/Vulvar 0 3 (1.5) 7 (3.5) 10 (5)
Bladder 0 5 (2.5) 7 (3.5) 12 (6)
Endometrial 1 (0.5) 3 (1.5) 0 4 (2)
Chloangiocarcinoma 0 2 (1) 2 (1) 4 (2)
Breast 0 3 (1.5) 3 (1.5) 6 (3)
Carcinoma of unknown
primary (CUP)
0 6 (3) 2 (1) 8 (4)
Gall bladder/
peri-ampullary
0 4 (2) 3 (1.5) 7 (3.5)
Lymphomaa 0 9 (4.5) 9 (4.5)
aLymphoma can only be classified into early or advanced stage
Table 3 Cancer type and stage of patients receiving non-cisplatin
based chemotherapy
Site of cancer Stage of tumor (N = 200) Total (%)
Early
(%)
Locally
advanced (%)
Metastatic
(%)
Lung 1 (0.5) 6 (3) 7 (3.5) 14 (7)
Gastric/GEJ 0 8 (4) 8 (4) 16 (8)
Pancreatic 0 8 (4) 6 (3) 14 (7)
Ovarian 0 7 (3.5) 9 (4.5) 16 (8)
Endometrial 0 3 (1.5) 3 (1.5) 6 (3)
Breast 4 (2) 28 (14) 28 (14) 60 (30)
Colorectal/Anal/Small
bowel
5 (2.5) 17 (8.5) 22 (11) 44 (22)
Lymphomaa 1 (0.5) 11 (5.5) 12 (6)
Sarcoma 1 (0.5) 7 (3.5) 4 (2) 12 (6)
Others 0 1 (0.5) 5 (2.5) 6 (3)
aLymphoma can only be classified into early or advanced stage
Table 1 Baseline Characteristics of the participants
Variables Cisplatin Group
n = 200 n (%)
Non-Cisplatin Group
n = 200 n (%)
1 Age (yrs)a 56 (11.9) 55 (9)
2 Males 108 (54%) 104 (52%)
3 Time to VTE (days)a 58 (17) 56 (13)
4 Stage
Early 10 (5%) 12 (6%)
Locally advanced 86 (43%) 92 (46%)
Metastatic 104 (52%) 96 (48%)
5 Presence of CVC 58 (29%) 55 (27%)
6 Surgery in 2 months 44 (22%) 56 (28%)
7 ECOG poor 16 (8%) 12 (6%)
8 Khorana Risk
low 39(19.5%) 55 (27.5%)
intermediate 129 (64.5%) 125 (62.5%)
high 32 (16%) 20 (10%)
9 Use of GCSF
never 88 (44%) 86 (43%)
<50% of cycles 71 (35.5%) 81 (40.5%)
>50% of cycles 6 (3%) 24 (12%)
All cycles 35 (17.5%) (9 9.5%)
aMean(SD)
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Our risk estimates are higher than a previously
reported meta-analysis where the risk was 1.67 (95%
CI: 1.25–2.23). The reason for this may be Seng et al,
in their meta-analysis pooled results from phase II to
III clinical trials. It is possible that patients in their
study were a highly selective group. Another
explanation could that we had highly specialised
investigations available and the chances of diagnosing
a VTE are higher in the present era than between
1990 and 2010 which is the study time for Seng et
al’s study [17].
The reason for choosing one month follow-up was
twofold. One, previous literature [13] had also taken
one month follow-up for development of DVT in
patients receiving Cisplatin based chemotherapy. This
study reported that 88% of patients developed TEE
within 100 days of initiation of treatment with
Cisplatin based regimens. Hence a period of 30 days
post completion of chemotherapy seems a reasonable
follow-up period for capturing most, if not all, events
occurring as a result of the drug intervention.
Secondly, we believe it is safe to assume that since
re-dosing of Cisplatin as a chemotherapeutic agent is
required within 3–4 weeks of the last dose; most
therapeutic as well as adverse effects of the drug are
neutralised within one month of last dosing. More-
over, if a VTE occurs one month after completion of
chemotherapy, it becomes further complex to attri-
bute it solely to chemotherapy effects as underlying
disease and other risk factors (e.g. CVC, immobility
etc.) are likely to play a much more important role.
Our major strength is being the first original re-
search reporting relative risk of VTE in Cisplatin
based regimens compared to non-Cisplatin. Aga Khan
University hospital is one of the two large centres for
the treatment of cancer in Pakistan. Hence, we were
Table 5 Chemotherapy regimens received by patients in the
non-cisplatin group
Type of chemotherapy Number of patients
(%) N = 200
Capecitabine + Oxaliplatin/5-FU + Leucovorin +
Oxaliplatin/Epirubicin + Oxaliplatin + Capecitabine
34 (17)
5-FU + Irinotecan + Leucovorin/5-FU + Irinotecan +
Leucovorin + Cetuximab/Irinotecan + Cetuximab
18 (9)
Doxorubicin + Cyclophophamide/5-FU + Epirubicin
+ Cyclophophamide/Epirubicin + Cyclophophamide
24 (12)
Paclitaxel/Paclitaxel + Herceptin 22 (11)
Docetaxel/Docetaxel + Herceptin 26 (13)
Adrimacycin + Ifosfamide 8 (4)
Carboplatin + Paclitaxel 34 (17)
CHOP/ABVD (Cyclophosphamide + Adriamycin +
Vincristine + Prednisone)/(Adriamycin + Bleomycin
+ Vinblastine + Dacarbazine)
12 (6)
VAC alternating with IE (Vincristine + Adriamycin +
Cyclophosphamide alternating with Ifosfamide
+ Etoposide)
4 (2)
5-FU + Oxaliplatin + Irinotecan + Leucovorin 8 (4)
Gemcitabine 6 (3)
Carboplatin + Gemcitabine 2 (1)
Others 2 (1)
Table 6 Comparison of the co-morbidities present in the two
groups
Co-morbid Number in cisplatin
group (%)
Number in noncisplatin
group (%)
N = 200 N = 200
Diabetes Mellitus 30 (15) 24 (12)
Hypertension 46 (23) 52 (26)
Coronary artery disease 10 (5) 08 (4)
Prior Atrial fibrillation 04 (2) 04 (2)
Prior history of TIA/Stroke 02 (1) 00
Renal Failure 00 00
Heart Failure 00 00
Table 7 Effect of Cisplatin dose on incidence of VTE
VTE status Cumulative dose of Cisplatin
(mg/m2) Mean (SD)
VTE occurred n = 31 471 (133.4)
VTE did not occur n = 169 322 (124)
Table 4 Chemotherapy regimens received by patients in the
cisplatin group
Type of chemotherapy Number of patients
(%) N = 200
Cisplatin + Gemcitabine 58 (29)
Cisplatin + Concurrent chemoradiation 28 (14)
Cisplatin + 5-FU/Cisplatin + Capecitabine 8 (4)
Cisplatin + 5-FU + Radiation/Cisplatin +
Capecitabine + Radiation
7 (3.5)
Docetaxel + Cispaltin + 5-FU 30 (15)
Epirubicin + Cisplatin + 5-FU/Epirubicin + Cisplatin 10 (5)
Docetaxel + Cispaltin + 5-FU + Cetuximab 4 (2)
DHAP (Dexamethasone + High dose ARA-C +
Cisplatin)
8 (4)
Cisplatin + Etoposide/Cisplatin + Etoposide +
Bleomycin
12 (6)
Cisplatin + Pemetrexed 16 (8)
Cisplatin + Navelbine 15 (7.5)
Cispaltin + Gemcitabine + Radiation 4 (2)
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able to obtain a reasonable sample with reliable data
on patients from the time of starting Cisplatin ther-
apy up till one month post chemotherapy. We were
able to maintain close follow up with all our patients
without attrition. There was no missing information
because we had access to medical records and
patients were coming for clinical follow ups regularly.
We chose a retrospective study design for feasibility
of sample size achievement and save resources.
The data was collected retrospectively but since all
the parameters were measured and documented in
hospital notes we assume there is minimal bias due
to recall. Although we may have missed some import-
ant confounders, one advantage of using hospital data
in this study was that the medical details were very
accurate and radiological investigations were easy to
follow hence minimizing misclassification of exposure
and outcome.
Site of cancer could be an important confounder
hence it was incorporated as one of the predictors of
Khorana score and it is reflected within the scoring.
Accordingly, we have adjusted our final model for
Khorana score to eliminate any confounding effect that
may have arisen due to the site of disease.
Polychemotherapy may potentially attribute higher
rates of VTE than single agent chemotherapy but this
fact is unlikely to affect our results as almost all
patients in both the groups received combination
chemotherapy (Tables 4 and 5). Patients who received
other platinum based therapies (Carboplatin,
Oxaliplatin), were included in the non-Cisplatin group
further highlighting the possibility that the increased
thrombogenic effect may be inherent to Cisplatin
alone rather than to the entire group of platinum
drugs.
This however, is also a potential bias and limitation
of our study as a difference in VTE incidence
between the different platinum drugs was not ex-
plored further. Our study had not been designed to
evaluate for any differences in VTE incidence between
the platinum compounds but further dissection and
analysis could indeed prove very interesting and is an
area which needs to be explored in future studies.
Another potential limitation of our study is the
absence of a universal screening test for assessment
of VTE status prior to initiation of chemotherapy in
patients. Although this would have been the ideal
method to ensure absence of VTE (target end-point)
in newly recruited patients, the retrospective nature
of our study meant that we had no control over in-
vestigations performed both prior to and during the
course of the study.
In the light of these finding we think there is an ur-
gent need to prospectively estimate the risk of VTE
in patients receiving Cisplatin based regimens. It is
immensely important to discover the pathophysiology
and identify genetic and molecular mechanisms of oc-
currence of VTE in these patients. Till then we
strongly recommend prophylaxis against VTE in high
risk groups to avoid serious morbidity or mortality.
We emphasize that it is extremely important to
develop potent and effective chemotherapeutic agents
with fewer side effects.
Conclusion
In our experience this is one of the first reports of
risk estimates of VTE with Cisplatin based
chemotherapeutic regimens. Focus should be laid on
discovery of newer and safer chemotherapeutic agents.
Till then, prophylaxis against VTE for patients
receiving Cisplatin based chemotherapy is highly
recommended. It is important to identify high risk
groups vulnerable to this side effect.
Appendix 1
Table 9 Adjusted Relative Risk of VTE due to Cisplatin based
Chemotherapy
β
coefficient
SE
(β)
Relative
Risk
95% CI
for RR
Cisplatin based chemotherapy 1.2 0.37 3.32 1.6–6.8
adjusted for ECOG, Khorana risk score, GCSF, presence of CVC and gender-log
likelihood =471.38
Table 10 Venous thromboembolic Events in Cisplatin based
and Non-Cisplatin based Chemotherapeutic regimes
Venous Thromboembolic
Events
Cisplatin
group
Non-Cisplatin
group
p value
n = 200 n = 200
DVT alone 18 7
PE alone 7 2
DVT + PE 5 2
Sudden death (defined as VTE) 1 0
Total 31 11 0.02
Table 8 Crude Relative Risk of Venous Thromboembolism in
Cisplatin based regimens
Incidence proportion Relative Risk (95% CI)
Cisplatin group 31/200 2.81* (1.4–4.2)
Non-Cisplatin group 11/200
*p < 0.05
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Appendix 2
Appendix 3
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